Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06113107

Acronym

Mero-Pyo

Enrollment

500

Registered

2023-11-02

Start date

2023-03-01

Completion date

2024-03-13

Last updated

2023-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudomonas

Keywords

Pseudomonas, Meropenem, Microbial susceptibility testing, EUCAST breakpoint, Antibiotic stewardship

Brief summary

Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of standard dose or high dose sensitivity. This modification seems to have favored an inappropriate overprescription of Meropenem (the only antibiotic made at standard dose) in Pseudomonas infections sensitive to other beta-lactams. In June 2021, it was therefore decided to mask sensitivity to carbapenems by default in the rendering of Pseudomonas antibiograms when the strain was sensitive to a narrower spectrum beta-lactam (restricted antibiogram). The aim of this study is to evaluate the impact of these changes in the antibiogram on antibiotic prescriptions.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Major subject (≥18 years old) * Subject with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022 * Subject not opposing the reuse of their data for the purposes of this research.

Exclusion criteria

* Subject having expressed opposition to participating in the study, * Pseudomonas spp strain resistant to all first-line beta-lactams (Piperacillin-Tazobactam, Ceftazidime, Céfepime and Aztreonam). * Pseudomonas spp strain resistant to Meropenem. * Lack of information on the antibiotic treatment undertaken.

Design outcomes

Primary

Measure	Time frame	Description
Proportion of Meropenem prescriptions in Pseudomonas spp bacteraemia susceptible to narrow-spectrum betalactams	Files analysed retrospectively from June 1, 2018 to November 30, 2022 will be examined	This study is retrospective, the analysis focuses on the medical records of patients treated at the Strasbourg University Hospital between June 1, 2018 and November 30, 2022.

Countries

France

Contacts

Primary ContactYvon RUCH, MD

yvon.ruch@chru-strasbourg.fr33 3 69 55 12 19

Outcome results